179 related articles for article (PubMed ID: 17631755)
1. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
Assous N; Gossec L; Dougados M; Kahan A; Allanore Y
Clin Exp Rheumatol; 2007; 25(3):504. PubMed ID: 17631755
[No Abstract] [Full Text] [Related]
2. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
Onishi S; Yoshio T; Nagashima T; Minota S
Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
[No Abstract] [Full Text] [Related]
3. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
4. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
5. New drugs for rheumatoid arthritis.
Messori A; Santarlasci B; Vaiani M
N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
[No Abstract] [Full Text] [Related]
6. Rheumatoid arthritis.
Burchini G; Orsi C
N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
[No Abstract] [Full Text] [Related]
7. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
8. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
9. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
De Stefano R; Frati E; Nargi F; Menza L
Clin Exp Rheumatol; 2011; 29(4):752-3. PubMed ID: 21906436
[No Abstract] [Full Text] [Related]
10. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
11. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL
Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
[No Abstract] [Full Text] [Related]
12. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
13. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
[No Abstract] [Full Text] [Related]
14. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
15. [Biologic therapy with anti-TNFα in rheumathoid arthritis].
Ferraccioli G
Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351
[TBL] [Abstract][Full Text] [Related]
16. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying antirheumatic drugs: enhancing efficacy by combination.
Schnabel A
Lancet; 2004 Feb; 363(9410):670-1. PubMed ID: 15001319
[No Abstract] [Full Text] [Related]
18. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
19. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
Blank N; Max R; Schiller M; Briem S; Lorenz HM
Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
[No Abstract] [Full Text] [Related]
20. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
